HK1214628A1 - 寡核苷酸癌症療法的給藥和施用 - Google Patents

寡核苷酸癌症療法的給藥和施用

Info

Publication number
HK1214628A1
HK1214628A1 HK16102626.0A HK16102626A HK1214628A1 HK 1214628 A1 HK1214628 A1 HK 1214628A1 HK 16102626 A HK16102626 A HK 16102626A HK 1214628 A1 HK1214628 A1 HK 1214628A1
Authority
HK
Hong Kong
Prior art keywords
oligonucleotide
dosing
administration
cancer therapies
therapies
Prior art date
Application number
HK16102626.0A
Other languages
English (en)
Inventor
Veloso Rodrigueza Wendi
Patel Sooch Mina
Kay Gaylor Shari
Adam Messmann Richard
James WOOLLISCROFT Michael
Original Assignee
Pronai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronai Therapeutics Inc filed Critical Pronai Therapeutics Inc
Publication of HK1214628A1 publication Critical patent/HK1214628A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16102626.0A 2012-11-05 2016-03-08 寡核苷酸癌症療法的給藥和施用 HK1214628A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261722526P 2012-11-05 2012-11-05
PCT/US2013/068516 WO2014071379A1 (en) 2012-11-05 2013-11-05 Dosing and administration of oligonucleotide cancer therapies

Publications (1)

Publication Number Publication Date
HK1214628A1 true HK1214628A1 (zh) 2016-07-29

Family

ID=49620303

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102626.0A HK1214628A1 (zh) 2012-11-05 2016-03-08 寡核苷酸癌症療法的給藥和施用

Country Status (10)

Country Link
US (1) US20150272980A1 (zh)
EP (1) EP2914722A1 (zh)
JP (1) JP2015536952A (zh)
KR (1) KR20150086294A (zh)
CN (1) CN104903450A (zh)
BR (1) BR112015010106A2 (zh)
CA (1) CA2890875A1 (zh)
HK (1) HK1214628A1 (zh)
IL (1) IL238638A0 (zh)
WO (1) WO2014071379A1 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10329570B2 (en) * 2014-07-31 2019-06-25 Academia Sinica Antagonistic PD-1 aptamer and its applications in cancer therapy related applications
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
IL284985B2 (en) 2015-02-18 2023-03-01 Enlivex Therapeutics R& D Ltd Combined immunotherapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
KR20170138534A (ko) 2015-04-21 2017-12-15 엔리벡스 테라퓨틱스 리미티드 치료적 혼주된 혈액 아폽토시스 세포 제제 및 이의 용도
WO2016170349A1 (en) * 2015-04-22 2016-10-27 Mina Therapeutics Limited C/ebp alpha sarna compositions and methods of use
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
KR20180120145A (ko) * 2016-02-02 2018-11-05 온코이뮨, 아이앤씨. 렙틴-결핍 병태를 치료하기 위한 cd24 단백질의 용도
EP3416661A4 (en) 2016-02-18 2020-03-04 Enlivex Therapeutics Ltd. COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR THE TREATMENT OF CANCER
WO2017143171A1 (en) * 2016-02-19 2017-08-24 Genisphere Llc Nucleic acid carriers and therapeutic methods of use
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN108926533B (zh) * 2017-05-24 2022-03-25 江苏天士力帝益药业有限公司 一种替西罗莫司脂质体及其制备方法
US20200384002A1 (en) * 2017-12-06 2020-12-10 Yale University Prodrugs Activated by Reduction in the Cytosol
WO2019165584A1 (zh) * 2018-02-27 2019-09-06 苏州大学张家港工业技术研究院 基于长链非编码 rna 的 bcl2 基因抑制剂
CN108310377A (zh) * 2018-03-13 2018-07-24 安徽瀚海博兴生物技术有限公司 一种将pd-1抗体与二甲双胍联合用于制备抗癌药物的应用
WO2019178489A1 (en) * 2018-03-16 2019-09-19 Bristol-Myers Squibb Company Metabolic enzyme activity and disulfide bond reduction during protein production
CN108586524B (zh) * 2018-05-28 2019-10-01 厦门大学 氟代氧化膦类化合物及其在正电子发射显像中的应用
CN110974954B (zh) * 2019-12-24 2021-03-16 珠海丽凡达生物技术有限公司 一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法
US20230119248A1 (en) * 2020-04-01 2023-04-20 University Of Cincinnati Materials and methods for immunosuppressive tumor microenvironment-targeted cancer therapy
CN117897140A (zh) * 2021-07-16 2024-04-16 塞拉特药物股份有限公司 用于制备脂质体制剂的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
CA2631931C (en) * 2005-12-01 2014-04-29 Pronai Therapeutics, Inc. Cancer therapies and pharmaceutical compositions used therein

Also Published As

Publication number Publication date
WO2014071379A1 (en) 2014-05-08
JP2015536952A (ja) 2015-12-24
US20150272980A1 (en) 2015-10-01
CN104903450A (zh) 2015-09-09
CA2890875A1 (en) 2014-05-08
EP2914722A1 (en) 2015-09-09
IL238638A0 (en) 2015-06-30
BR112015010106A2 (pt) 2017-08-22
KR20150086294A (ko) 2015-07-27

Similar Documents

Publication Publication Date Title
HK1214628A1 (zh) 寡核苷酸癌症療法的給藥和施用
HK1216105A1 (zh) 治療劑的遞送
IL264901B (en) Administration of kynurenine-reducing enzymes for tumor treatment
IL239557B (en) Microarray for providing therapeutic material and methods for use
HK1210065A1 (zh) 乾粉末藥物傳遞系統和方法
HK1209021A1 (zh) 納米標靶藥物的療法
ZA201506984B (en) Microarray for delivery of therapeutic agent and methods of use
EP2844663A4 (en) Novel TETRAGALNAC-CONJUGATES AND METHOD OF RELEASING OLIGONUCLEOTIDES
PL2716291T3 (pl) Połączenie opioidów i leków przeciwnowotworowych do leczenia nowotworów
EP2710137A4 (en) COMBINATION OF LOCAL AND SYSTEMIC IMMUNOMODULATORY THERAPIES FOR IMPROVED TREATMENT OF CANCER
EP2951739C0 (en) VARIABLE DOSE DELIVERY OF DRUG
HK1206605A1 (zh) 包括給藥 和威羅菲尼的黑色素瘤的組合療法
EP4005604C0 (en) ADMINISTRATION OF MEDICINES
EP2836501A4 (en) RNA APTAMERS FOR THERAPEUTIC AND DIAGNOSTIC ADMINISTRATION ON PANCREAS CRAB CELLS
IL237373A0 (en) Method for dosing a sedative
EP2934636A4 (en) DOUBLE CHAMBER MIXING SYRINGES AND METHODS OF USE THEREOF
ZA201405949B (en) Pharmaceutical preparation containing and antivirally active dihydroquinazoline derivative
IL237300A0 (en) Drug delivery systems and methods for treating prostate gland diseases containing gemcitabine
AP2015008208A0 (en) Pharmaceutical administration forms comprising
EP2911692A4 (en) USE OF ENDOCYTOSE INHIBITORS AND ANTIBODIES FOR ANTICANCER THERAPY
GB201319437D0 (en) Delivery of drugs
EP2859523A4 (en) RANGE OF MEDICINES AND PRODUCTS OF WELLNESS
GB201202945D0 (en) Novel cancer therapies and methods
GB201213729D0 (en) Manufacture of insoluble drugs
GB201208492D0 (en) Formulations of generic drugs against cancer and infectious diseases